FELIQS Receives U.S. FDA Fast Track Designation for FLQ-101, a First-in-class Small Molecule to Prevent Retinopathy of Prematurity

FUKUOKA, Japan & NEW YORK--(BUSINESS WIRE)--FELIQS®, a clinical stage multinational biopharmaceutical company focused on the development of first-in-class small molecules targeting lipid oxidation, announced today that the U.S. Food and Drug Administration (FDA) has granted its lead asset, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). The company plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in 1Q2025. The FDA g